BioGend Therapeutics (TPEX:6733) - Share price, News & Analysis

6733 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

6733 Stock Overview

BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products.

Rewards

Earnings have grown 1.3% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue (NT$13M)

Does not have a meaningful market cap (NT$2B)

BioGend Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioGend Therapeutics
Historical stock prices
Current Share Price	NT$23.15
52 Week High	NT$29.05
52 Week Low	NT$22.00
Beta	0.91
1 Month Change	-10.27%
3 Month Change	-8.86%
1 Year Change	-11.47%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-30.06%

Recent News & Updates

Mar 24

Here's Why We're Not At All Concerned With BioGend Therapeutics' (GTSM:6733) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

	6733	TW Biotechs	TW Market
7D	-3.3%	1.9%	2.0%
1Y	-11.5%	10.0%	1.7%

Return vs Industry: 6733 underperformed the TW Biotechs industry which returned 10% over the past year.

Return vs Market: 6733 underperformed the TW Market which returned 1.7% over the past year.

Price Volatility

Is 6733's price volatile compared to industry and market?
6733 volatility
6733 Average Weekly Movement	4.0%
Biotechs Industry Average Movement	5.3%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.3%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 6733 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 6733's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2016	n/a	Steve Lin	https://www.biogend.com

BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. The company is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. BioGend Therapeutics Co., Ltd.

BioGend Therapeutics Fundamentals Summary

How do BioGend Therapeutics's earnings and revenue compare to its market cap?
6733 fundamental statistics
Market Cap	NT$2.39b
Earnings (TTM)	-NT$136.28m
Revenue (TTM)	NT$13.15m

181.5x

P/S Ratio

-17.5x

P/E Ratio

Is 6733 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
6733 income statement (TTM)
Revenue	NT$13.15m
Cost of Revenue	NT$8.16m
Gross Profit	NT$4.99m
Other Expenses	NT$141.28m
Earnings	-NT$136.28m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.32
Gross Margin	37.97%
Net Profit Margin	-1,036.29%
Debt/Equity Ratio	0%

How did 6733 perform over the long term?

See historical performance and comparison

Valuation

Is BioGend Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

2.84x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6733's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6733's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: 6733 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 6733 is unprofitable, so we can't compare its PE Ratio to the TW market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6733's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 6733 is good value based on its PB Ratio (2.8x) compared to the TW Biotechs industry average (3.8x).

Future Growth

How is BioGend Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

125.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioGend Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has BioGend Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

1.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6733 is currently unprofitable.

Growing Profit Margin: 6733 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 6733 is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.

Accelerating Growth: Unable to compare 6733's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6733 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).

Return on Equity

High ROE: 6733 has a negative Return on Equity (-16.68%), as it is currently unprofitable.

Financial Health

How is BioGend Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6733's short term assets (NT$682.6M) exceed its short term liabilities (NT$15.5M).

Long Term Liabilities: 6733's short term assets (NT$682.6M) exceed its long term liabilities (NT$53.0M).

Debt to Equity History and Analysis

Debt Level: 6733 is debt free.

Reducing Debt: 6733 has no debt compared to 5 years ago when its debt to equity ratio was 6.7%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6733 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6733 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 1.3% each year

Dividend

What is BioGend Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6733's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6733's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6733's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6733's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6733 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Steve Lin

no data

Tenure

Dr. Steve Lin D.Sc., serves as Chief Executive Officer at BioGend Therapeutics Co., Ltd. Dr. Lin served as Chief Technology Officer of Exactech Inc. Dr. Lin served as Advanced Technology Manager of Orthoma...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/19 00:00
End of Day Share Price	2022/05/18 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31